Table 1.
Recent studies focusing on the association of multiple myeloma and systemic light-chain (AL) amyloidosis.
| Author/Year | Period | Primary Disease | N | n (%N) |
|---|---|---|---|---|
| Pardadani, A. et al., 2003 [6] | 1991–1996 | AL | 147 | 20 MM (14) |
| Kourelis, T.V. et al., 2013 [7] | 2000–2010 | AL | 1255 | 100 MM (8) |
| Dinner, S. et al., 2013 [8] | 2005–2011 | AL | 46 | 21/37 MM (57) |
| Jimenez-Zepeda, V. et al., 2022 [9] | 2010–2019 | AL | 215 | 64 MM (29.8) |
| Yoon. S.E. et al., 2022 [10] | 1995–2018 | AL | 302 | 59 MM (19.5) |
| He, H. et al., 2023 [11] | 2012–2021 | AL | 142 | 62 MM (43.7) |
| Vela-Ojeda, J. et al., 2009 [12] | 1989–2000 | MM | 201 | 68 AL (33.8) |
| Siragusa, S. et al., 2011 [13] | 1993–2003 | MM/SMM | 144 | 2 * AL (1.4) |
| Usnarka-Zubkiewicz, L. et al., 2014 [14] | ND | MM | 70 | 18 AL (25.7) |
| Ríos-Tamayo, R. et al., 2015 [15] | 1985–2014 | MM | 303 | 7 AL (2.3) |
| Xu, J. et al., 2021 [16] | 2010–2018 | MM/SMM | 158 | 49 AL (31) |
Abbreviations: AL: systemic AL amyloidosis; MM: multiple myeloma; N: number of patients with de primary disease; n: number of patients with the associated alternative disease; ND: not determined; SMM: smoldering MM; *: retrospective study performed in bone marrow biopsies.